ADGM vs MEDP vs NVCR vs RXRX

For growth investors, Recursion Pharmaceuticals, Inc.

(RXRX) is the stronger pick with 26. 9% revenue growth year-over-year, versus -10. 3% for Adagio Medical Holdings, Inc. (ADGM). Medpace Holdings, Inc. (MEDP) offers the better valuation at 28. 1x trailing P/E (25. 0x forward), making it the more compelling value choice. Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Medpace Holdings, Inc.

(MEDP) delivered a total return of +159. 4%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: MEDP returned +1426% versus ADGM's -89. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Adagio Medical Holdings, Inc.

(ADGM) is the lower-risk stock at 0. 87β versus Recursion Pharmaceuticals, Inc. 's 2. 99β — meaning RXRX is approximately 245% more volatile than ADGM relative to the S&P 500. On balance sheet safety, Recursion Pharmaceuticals, Inc. (RXRX) carries a lower debt/equity ratio of 7% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Recursion Pharmaceuticals, Inc.

(RXRX) is pulling ahead at 26. 9% versus -10. 3% for Adagio Medical Holdings, Inc. (ADGM). On earnings-per-share growth, the picture is similar: Adagio Medical Holdings, Inc. grew EPS 27. 2% year-over-year, compared to 14. 8% for Recursion Pharmaceuticals, Inc.. Over a 3-year CAGR, RXRX leads at 23. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Medpace Holdings, Inc.

(MEDP) is the more profitable company, earning 17. 8% net margin versus -199. 9% for Adagio Medical Holdings, Inc. — meaning it keeps 17. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MEDP leads at 21. 1% versus -232. 3% for ADGM. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RXRX: 236.

4% to $11. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Medpace Holdings, Inc.

(MEDP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 21), +1426% 10Y return). Recursion Pharmaceuticals, Inc. (RXRX) carries a higher beta of 2. 99 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MEDP: +1426%, RXRX: -81. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ADGM is a small-cap quality compounder stock; MEDP is a mid-cap high-growth stock; NVCR is a small-cap quality compounder stock; RXRX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.